APEN - Apollo Endosurgery, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.94
0.00 (0.73%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.89
Open6.94
Bid0.00 x 1800
Ask13.91 x 2200
Day's Range6.11 - 6.94
52 Week Range3.75 - 9.65
Volume42,424
Avg. Volume68,350
Market Cap151.84M
Beta0.30
PE Ratio (TTM)N/A
EPS (TTM)-1.75
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.19
Trade prices are not sourced from all markets
  • Business Wire23 hours ago

    Apollo Endosurgery and Istituto Clinico Humanitas in Milano, Italy Establish European Registry for Flexible Endoscopic Suturing Procedures in Gastrointestinal Applications

    Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced today an agreement with Istitudo Clinico Humanitas to establish a multicenter, retrospective, data repository for gastrointestinal applications performed using Apollo’s OverStitch™ Endoscopic Suturing System. Professor Alessandro Repici, Director of the Digestive Endoscopy Unit of Istituto Clinico Humanitas, will serve as the Principal Investigator. Endoscopic suturing can be used to support a wide variety of therapeutic, gastrointestinal endoscopic procedures.

  • What Does Apollo Endosurgery Inc’s (NASDAQ:APEN) Ownership Structure Look Like?
    Simply Wall St.7 days ago

    What Does Apollo Endosurgery Inc’s (NASDAQ:APEN) Ownership Structure Look Like?

    If you want to know who really controls Apollo Endosurgery Inc (NASDAQ:APEN), then you’ll have to look at the makeup of its share registry. Generally speaking, as a company grows,Read More...

  • GlobeNewswirelast month

    Analysis: Positioning to Benefit within Quanex Building Products, Molecular Templates, Atara Biotherapeutics, Forward Industries, Apollo Endosurgery, and Myomo — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK,, Aug. 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • Business Wire2 months ago

    Apollo Endosurgery, Inc. Reports Second Quarter 2018 Results

    OverStitch™ Product Sales Increase 37% Year-Over-Year

  • Business Wire2 months ago

    Apollo Endosurgery, Inc. to Report Second Quarter Results on August 8, 2018

    Apollo Endosurgery, Inc. , a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that the Company is scheduled to release its financial results for the second quarter ended June 30, 2018 on Wednesday, August 8, 2018, after the U.S.

  • Business Wire3 months ago

    Apollo Endosurgery Receives Special 510(k) Clearance for OverStitch™ Sx Endoscopic Suturing System

    Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced today that it has received Special 510(k) clearance from the U.S. Food and Drug Administration for OverStitch™ Sx Endoscopic Suturing System. The OverStitch Sx System, a new, full-thickness flexible endoscopic suturing system, received initial 510(k) clearance in November 2017. The Special 510(k) addressed an accessory to the system that is intended to ease the attachment of the device to compatible endoscopes (single-channel endoscopes with diameters ranging from 8.8mm to 9.8mm).

  • Business Wire3 months ago

    Apollo Endosurgery, Inc. Announces Closing of Public Offering of Common Stock and Underwriter’s Full Exercise of Over-Allotment Option

    Apollo Endosurgery, Inc. (APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced the closing of its previously announced underwritten public offering of 4,309,090 shares of its common stock, including 562,055 shares sold pursuant to the underwriter’s exercise in full of its option to purchase additional shares to cover over-allotments. Gross proceeds from the offering at a public offering price of $5.50 per share, before underwriting discounts and commissions and offering expenses, were approximately $23.7 million. All of the common stock was offered and sold by Apollo.

  • Benzinga3 months ago

    Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 19) AngioDynamics, Inc. (NASDAQ: ANGO ) Array Biopharma Inc (NASDAQ: ...

  • Business Wire3 months ago

    Apollo Endosurgery, Inc. Announces Pricing of $20.6 Million Public Offering of Common Stock

    Apollo Endosurgery, Inc. (APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced the pricing of an underwritten public offering of 3,747,035 shares of its common stock at a public offering price of $5.50 per share for gross proceeds of approximately $20.6 million. All of the common stock is being offered by Apollo. In addition, Apollo has granted the underwriter a 45-day option to purchase up to an additional 562,055 shares of common stock.

  • Business Wire3 months ago

    Apollo Endosurgery, Inc. Announces Commencement of Public Offering of Common Stock

    Apollo Endosurgery, Inc. (“Apollo”) (APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. All of the common stock is being offered by Apollo. In addition, Apollo expects to grant the underwriter a 45-day option to purchase additional shares of common stock.

  • Business Wire4 months ago

    Apollo Endosurgery Announces Presentation of Mayo Clinic’s Clinical Study of ORBERA® Intragastric Balloon in Patients with Nonalcoholic Steatohepatitis (NASH) at Digestive Disease Week® 2018 (DDW)

    Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced today’s presentation of results from Mayo Clinic’s prospective open-label study of the ORBERA® Intragastric Balloon in patients with Nonalcoholic Steatohepatitis (“NASH”) at Digestive Disease Week 2018. The FDA-approved study demonstrated the significant benefits of weight loss with the ORBERA Intragastric Balloon in patients with NASH and nonalcoholic fatty liver disease (NAFLD).

  • Business Wire4 months ago

    Apollo Endosurgery Announces Presentation of Mortality and Inpatient Costs of Revisional Bariatric Surgery

    Apollo Endosurgery, Inc. , a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced the presentation of the study results “Mortality and Inpatient Costs of Revisional Bariatric Surgery: A Nationwide Analysis” at Digestive and Disease Week in Washington, DC.

  • Business Wire4 months ago

    Apollo Endosurgery Announces FDA Approval of Revised Labeling for the ORBERA® Intragastric Balloon System

    Apollo Endosurgery, Inc. a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced today that the United States Food and Drug Administration has approved updates to the ORBERA® Intragastric Balloon System’s U.S.

  • Business Wire4 months ago

    Apollo Endosurgery Announces Presentation of Intragastric Balloon Comparison Study at Digestive Disease Week® 2018 titled: “Fluid-Filled Intragastric Balloons are Superior to Gas-Filled Balloon”

    Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced Digestive Disease Week presentation of a meta analysis that concluded fluid-filled balloons, like the ORBERA® Intragastric Balloon, have superior weight loss results to gas-filled balloons.

  • Business Wire4 months ago

    Apollo Endosurgery Appoints Dr. Julie Shimer to Board of Directors

    Apollo Endosurgery, Inc. (“Apollo”) (APEN) today announced that Dr. Julie Shimer, who led Welch Allyn Inc. and Vocera Communications as its Chief Executive Officer and President, has been appointed to Apollo’s Board of Directors by shareholder election on May 23, 2018. Additionally, John Creecy, CEO of Remeditex Ventures, has retired from the Board following a 7-year tenure. Dr. Shimer will join eight other directors, four of whom are independent under the rules and regulations of the United States Securities and Exchange Commission, and will serve as the board’s Chair of the Compensation Committee.

  • Business Wire4 months ago

    Apollo Endosurgery to Feature Industry-Advancing Endoscopic Procedure Portfolio During Digestive Disease Week® 2018 Conference

    Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced today its participation during Digestive Disease Week 2018 (“DDW”). DDW will be held June 2-5, 2018 at the Walter E. Washington Convention Center in Washington, D.C. Apollo’s endoscopy and endobariatric products, including the OverStitch™ Endoscopic Suturing System and the ORBERA® Intragastric Balloon, will be featured in 55 clinical presentations being presented at DDW.

  • Business Wire4 months ago

    Apollo Endosurgery Announces Spanish Study of ESG in NASH Patients

    Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced today the enrollment of the first patient in a multicenter, randomized, controlled, double-blind study of the efficacy and safety of Endoscopic Sleeve Gastroplasty (“ESG”) using Apollo’s OverStitch™ Endoscopic Suturing System, in patients with non-alcoholic steatohepatitis (“NASH”). The study is funded by a Beca FIS Grant awarded to the Foundation of the Hospital Universitario Puerta de Hierro Majadahonda by the Ministry of Health of the Spanish Government. The study will involve four National Health System Hospitals, led by Professor José Luis Calleja, MD from Hospital Universitario Puerta de Hierro Majadahonda - Universidad Autónoma de Madrid, as Principal Investigator.

  • Business Wire5 months ago

    Apollo Endosurgery Establishes European Registry for Bariatric Flexible Endoscopic Suturing Procedures

    Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced today the establishment of a multicenter, longitudinal, data repository for Endoscopic Sleeve Gastroplasty (“ESG”) and Gastrojejunal Anastomotic Outlet Revision procedures. The prospective registry will collect outcomes related to the safety and effectiveness of procedures performed with Apollo’s OverStitch™ Endoscopic Suturing System.

  • ACCESSWIRE5 months ago

    Free Post Earnings Research Report: Edwards Lifesciences’ Adjusted Sales Grew 9.3%; Adjusted EPS Surged 30%

    LONDON, UK / ACCESSWIRE / May 08, 2018 / If you want access to our free earnings report on Edwards Lifesciences Corp. (NYSE: EW), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EW. Edwards Lifesciences reported its first quarter fiscal 2018 operating and financial results on April 24, 2018. Additionally, the Company provided guidance for the upcoming quarter and fiscal year.

  • Business Wire5 months ago

    Apollo Endosurgery, Inc. Reports First Quarter 2018 Results

    Apollo Endosurgery, Inc. , a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced financial results for the first quarter ended March 31, 2018.

  • Business Wire5 months ago

    Apollo Endosurgery, Inc. to Report First Quarter Results on May 3, 2018

    Apollo Endosurgery, Inc. , a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that it plans to release its financial results for the first quarter ended March 31, 2018 on Thursday, May 3, 2018, after the U.S.

  • Business Wire5 months ago

    Apollo Endosurgery Announces Approval of the New 12-month Weight Loss Balloon - ORBERA365™ - in the Kingdom of Saudi Arabia

    Apollo Endosurgery, Inc. (“Apollo”) (APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that the Saudi Food and Drug Authority (SFDA) has approved the ORBERA365™ Managed Weight Loss System and has issued a Medical Device Marketing Authorization (MDMA) for the product. This MDMA allows Apollo Endosurgery to market ORBERA365 in the Kingdom of Saudi Arabia with its exclusive distribution partner, AL-Nozha Medical. The ORBERA365 Managed Weight Loss System doubles the indwell period of the #1 intragastric balloon in the world from 6 months to a 12 month treatment period.

  • Business Wire6 months ago

    Apollo Endosurgery Announces Conclusion of LAP-BAND® Low BMI Post-Approval Study

    Apollo Endosurgery, Inc. , a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that the FDA has approved the termination of the LAP-BAND® Lower Body Mass Index Post-approval study .